The new patents was issued over Q3 and Q4 of 2014
BioTime has announced the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, OrthoCyte Corporation, ES Cell International, OncoCyte Corporation, and ReCyte Therapeutics. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies' patent estate of over 600 patents and patent applications pending worldwide, which is the largest known patent estate in the field of pluripotent stem cell technology for human therapeutic application, also known as regenerative medicine.
"BioTime and its subsidiaries are focused on developing and commercialising a broad portfolio of innovative cellular therapeutics and diagnostic products, while also continuing to build value in other ways, such as through the addition of new patents to our industry-leading intellectual property estate," said Dr Michael D West, BioTime's CEO. He added, "We are making significant strides in patenting our core platform of pluripotent stem cell technology and strengthening our competitive position in regenerative medicine. We plan to utilize our strengthened patent position to drive value for our shareholders as the field of regenerative medicine begins to address the large and growing markets associated with chronic and age-related degenerative disease."
The New Patents Owned by BioTime or one of its subsidiaries are European patent 1809739, Canada patent 2559854 and China patent ZL200580008779.0, South Korea patent 1543500B , Canada patent 2468335, Israel patent 208116, Singapore patents 18809, 176957 and 177694, Australia patents 2011258249,00735127, Israel patent 179785, and in-licensed Patents, United States patent 8921104 and 8,815804.